
Opinion|Videos|December 27, 2024
The Future of Bispecific Therapy for R/R Multiple Myeloma
Author(s)Binod Dhakal, MD, MS
Panelist discusses how there are many significant attributes of the bispecific antibody, which has broader applicability and can be used in widespread community centers. There are more community centers that are staring to use bispecific antibodies, and there is now a much lower rate of CRS and immune effector cell–associated neurotoxicity syndrome (ICANS).
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What is the future for the treatment of RRMM?
- What are the potential opportunities that can improve patient access to emerging therapies and optimal care?
- What clinical pearls can you share for community providers treating RRMM patients with bispecifics?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
FDA Grants FTD to GPRC5D Bispecific LBL-034 for R/R Multiple Myeloma
4
Multiomic Real-World Data Predict Outcomes in Metastatic Breast Cancer
5



















